Development of effective immunotherapy for the treatment of patients with cancer

Journal of the American College of Surgeons

Volumn 198, Issue 5, 2004, Pages 685-696

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

IL 2; interleukin 2; major histocompatability complex; MHC; TIL; tumor infiltrating lymphocyte

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER; CANCER IMMUNOTHERAPY; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

ANTIGENS, NEOPLASM; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 2142646416     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2004.01.025     Document Type: Conference Paper

References (38)

1. Morgan D.A., Ruscetti F.W., Gallo R.G. Selective in vitro growth of T-lymphocytes from normal bone marrow. Science. 193:1976;1007-1008
2. Taniguchi T., Matsui H., Fujita T. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 302:1983;305-307
3. Rosenberg S.A., Grimm E.A., McGrogan M., et al. Biological activity of recombinant human interleukin-2 produced in E. coli. Science. 223:1984;1412-1414
4. Rosenberg S.A., Mule J.J., Spiess P.J., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant IL-2. J Exp Med. 161:1985;1169-1188
5. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313:1985;1485-1492
6. Lotze M.T., Chang A.E., Seipp C.A., et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer responses, treatment related morbidity and histologic findings. JAMA. 256:1986;3117-3124
7. Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 identification of the antigens mediating response. Ann Surg. 228:1998;307-319
8. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1986;1318-1321
9. Spiess P.J., Yang J.C., Rosenberg S.A. In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 79:1987;1067-1075
10. Rosenberg S.A., Packard B.S., Aebersold P.M., et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med. 319:1988;1676-1680
11. Rosenberg S.A., Yannelli J.R., Yang J.C., et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst. 86:1994;1159-1166
12. Rosenberg S.A., Aebersold P.M., Cornetta K., et al. Gene transfer into humans immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 323:1990;570-578
13. Rosenberg S.A., Anderson W.F., Blaese M., et al. The development of gene therapy for the treatment of cancer. Ann Surg. 218:1993;455-464
14. Rosenberg S.A. Gene therapy for cancer. JAMA. 268:1992;2416-2419
15. Rosenberg S.A. Progress in human tumor immunology and immunotherapy. Nature. 411:2001;380-384
16. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:1999;281-287
17. Kawakami Y., Eliyahu S., Delgado C.H., et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 91:1994;6458-6462
18. Kawakami Y., Eliyahu S., Delgado C.H., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91:1994;3515-3519
19. Brichard V., Van Pel A., Wolfel T., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 178:1993;489-495
20. Rosenberg S.A., White D.E. Brief report: vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother. 183:1996;81-84
21. Robbins P.F., El-Gamil M., Li F., et al. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol. 159:1997;303-308
22. Wang R.-F., Parkhurst M.R., Kawakami Y., et al. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med. 183:1996;1131-1140
23. Robbins P.F., El-Gamil M., Li Y.F., et al. A mutated B-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 183:1996;1185-1192
24. Wang R.-F., Wang X., Rosenberg S.A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med. 189:1999;1659-1667
25. Van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647
26. Boon T., Coulie P.G., Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 18:1997;267-268
27. Jager E., Chen Y.T., Drijfhout J.W. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1 definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 187:1998;265-270
28. Wang R.-F., Johnston S.L., Zeng G., et al. A breast and melanoma-shared tumor antigen T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 161:1998;3596-3606
29. Rosenberg S.A., Zhai Y., Yang J.C., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 90:1998;1894-1900
30. Rosenberg S.A., Yang J.C., Sherry P.M., et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Human Gene Therapy. 14:2003;709-714
31. Panelli M.C., Wunderlich J., Jeffries J., et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 23:2000;487-498
32. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 9:2003;2973-2980
33. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:1998;321-327
34. Parkhurst M.R., Salgaller M.L., Southwood S., et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0210 binding residues. J Immunol. 157:1996;2539-2548
35. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 11:2002;999-1005
36. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:2003;339-342
37. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science. 298:2002;850-854
38. Dudley M.E., Wunderlich J.R., Shelton T.E., et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 26:2003;332-342